Most men over age 40 try to prevent prostate cancer, survey shows
Most men over the age of 40 years attempt to protect themselves against prostate cancer, according to a new survey by researchers at Thomas Jefferson University?s Kimmel Cancer Center in Philadelphia.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.